Adolfo Poma

@apoma.bsky.social

GōMartini 3 developer. 🇵🇪 Dad. Fascinated by how pathogens interact with cells. Deputy editor at JSB/JSBX @Elsevier 🌐 http://pomalab.ippt.pan.pl/web/

Discussing my personal experiences navigating neurodiversity in academia, and what worked for me to cope better in my latest column for EMBO Reports. Please share with anyone who might find this useful/helpful. You are not alone. www.embopress.org/doi/full/10....

A personal journey through academia as a neurodiverse scientist | EMBO reports

EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.

embopress.org

Happy to share the latest work from the lab, led by @mudgal17.bsky.social‬, in collaboration with the Weis lab @ethzurich.bsky.social. How do nuclear membranes fuse during NPC assembly? We answer this question in our latest work, where we identify a new mechanism for membrane fusion… (1/13)

bioRxiv Cell Biology@biorxiv-cellbio.bsky.social · last yr.

A conserved mechanism of membrane fusion in nuclear pore complex assembly https://www.biorxiv.org/content/10.1101/2025.07.21.665908v1

🚀 New preprint! We present an optimized contact map protocol for GōMartini 3 protein-assembly simulations. 🔹 Uses high-freq contacts from MD 🔹 Cuts contact sets by ~20–30% while keeping stability 🔹 Improves exploration of metastable states (e.g. SARS-CoV-2 spike) Preprint: doi.org/10.1101/2025...

Bild

🚨 Preprint! Our work complements affinity studies for antibodies (Ab) design 🔹 Mechano­stability as design criterion for Abs against viral escape. 🔹 Two-chain topology: H chain bears force, L chain reinforces via inter-chain contacts. Great work by @fcofas.bsky.social www.biorxiv.org/cgi/content/...

A Comparative Nanomechanical Study of Antibody and Nanobody Binding to SARS-CoV-2 Variants

The receptor-binding domain of the SARS-CoV-2 spike protein is the principal target of neutralizing antibodies (Abs) and nanobodies (Nbs). Although their thermodynamic binding properties have been ext...

biorxiv.org